Health ❯ Healthcare ❯ Clinical Trials

Drug Efficacy

Patient Outcomes Weight Loss Results Side Effects Combination Therapy Semaglutide Weight Loss Drugs Weight Loss Medications Patient Safety Lenacapavir Wegovy Trials

FDA Expands Approval of Pfizer’s Hympavzi to Younger Children and Patients With Inhibitors

The decision expands access to a once‑weekly under‑the‑skin prophylaxis for ages 6–11, adding an option for 12‑plus patients who have inhibitors.

Stories older than 24h

New Trials Show Daily Pills Can Help Maintain Weight Loss After GLP-1 Injections

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

Sarepta Reports Early siRNA Data Showing Muscle Delivery as Shares Surge

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

For Third Time, FDA Rejects Aldeyra’s Dry-Eye Drug Reproxalap Over Efficacy

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

NICE Recommends First Vitiligo Repigmentation Cream for NHS Use in England

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

G-BA Finds No Added Benefit for Alzheimer’s Drug Leqembi in Germany

GLP‑1 Use Under Scrutiny After Study on Tolerability and Delhi OTC Sales

Kidney Drug Finerenone Shows Early Promise in Restoring Egg Development in Early Menopause

Randomized Trial Finds Solriamfetol Improves Alertness in Early-Morning Shift Workers

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

NICE Backs Talazoparib–Enzalutamide for NHS Use in England

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut